Given the beneficial effects seen in mouse models of AD and the T2DN-ADRD rat model, clinical trials are warranted to assess the effectiveness of SGLT2 inhibitors in AD, irrespective of the diabetic status of the patients. This evidence concerns the gene SLC5A2 and Alzheimer disease.